Skip to content

Psychedelic-assisted therapy research published in 2024

Page 4 of 10: studies 61 to 80 of 192, newest first. Back to the psychedelic-assisted therapy overview

Studies

Psychedelics as a potential treatment for tobacco use disorder: a systematic review.

Discover Mental Health September 17, 2024 S K Spoelstra, Robert A Schoevers, S D Venema et al. 8 citations

Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation therapies is limited, leading to a growing interest in alternative treatment approaches such as psychedelics. The aim of this review is to evaluate the scientific evidence regarding the role of psychedelics in smoking cessation. To identify relevant...

DOI: 10.1007/s44192-024-00095-0 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Smoking cessation Addiction treatment Psilocybin research +1

Lost in translation? Qualitative interviews with Australian psychedelic-assisted therapy trial clinicians.

Psychology and Psychotherapy Theory Research and Practice September 16, 2024 Michaela Barber, John Gardner, Paul Liknaitzky et al. 3 citations

BACKGROUND: Policy changes in Australia mean that psychedelic-assisted therapy (PAT) is now available to consumers outside of clinical trials. Yet, the regulatory frameworks guiding the practice of PAT are underdeveloped, and the evidence base for guiding clinical practice is diverse and emerging, resulting in anticipated challenges in translation to community practice. Mental health clinicians...

The Psychedelic Renaissance: A Catholic Perspective.

Linacre Q September 15, 2024 Thomas Carroll 4 citations

. This has led to widespread interest in psychedelic compounds being used for recreation, treatment of mental illness and addiction, and even the so-called "enhancement" of individuals and society. This renewed interest in psychedelics has resulted in seemingly endless publications in both the popular and the academic press, including authors from fields as diverse as philosophy, theology,...

Belief change and agnostic frames in psychedelic research and clinical contexts

Philosophical Perspectives on Psychedelic Psychiatry September 13, 2024 David B. Yaden, Sandeep M. Nayak, Roland R. Griffiths 4 citations

Abstract The proportion of people who change their metaphysical beliefs after psychedelic experiences is not yet known with specificity. However, it appears that belief changes can occur in some cases, and evidence more precisely estimating the prevalence and magnitude of such belief changes is accruing. The evidence for metaphysical belief changes is reviewed and the potential psychological...

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases

Cochrane Database of Systematic Reviews September 11, 2024 Sivan Schipper, Kabir Nigam, Yasmin Schmid et al. 34 citations

Implications for practice Psychedelic-assisted therapy with classical psychedelics (psilocybin, LSD) may be effective for treating anxiety, depression, and possibly existential distress, in people facing a life-threatening disease. Psychedelic-assisted therapy seemed to be well tolerated, with no treatment-emergent serious adverse events reported in the studies included in this review. However,...

DOI: 10.1002/14651858.cd015383.pub2 (opens in new tab) Full text (opens in new tab) Distress Depression economics Existentialism Psychotherapist +2

Psychedelic medicine in psychiatry residency training: a survey of psychiatric residency program directors.

International Review of Psychiatry September 11, 2024 Mary E. Yaden, Terence H. W. Ching, Noam Goldway et al. 2 citations

OBJECTIVE: The growth of psychedelic medicine creates new challenges in psychiatric education as physicians may soon be responsible for prescribing a number of psychedelic interventions. Despite this growing need for educated providers, very little is known about the training psychiatry residents receive in psychedelic medicine. We conducted a survey to determine the current educational...

DOI: 10.1080/09540261.2024.2397039 (opens in new tab) Psychedelic-assisted therapy Psychedelic therapies Innovative treatments Promising new modalities +11

Psychedelic-assisted therapy: Magical thinking or a meaningful treatment for mental illness

UCC Student Medical Journal September 4, 2024 Megha Kodancha

Psychedelics are psychoactive substances that are known to alter perception, alter mood, and affect numerous cognitive processes. Throughout history, psychedelics were utilized in ceremonies and rituals, and in the 20th century, their utilization in psychiatry began. In the 1960s they became a banned substance and are only recently being revisited for their benefits. The main forms of...

Is Personal Experience Essential for Effective Psychedelic Therapists?: The Challenges of Small, Accumulating Therapist Effects.

Psychedelic Medicine September 4, 2024 Mitch Earleywine, Samantha G. Gomez 5 citations

Many authors assert that those who provide psychedelic-assisted therapy (PAT) likely benefit from having personal experiences with psychedelics (PEP) as part of their training. Meta-analytic results confirm advantages of experiential learning in other forms of training as well. Potential PAT clients, especially those who identify as members of underrepresented groups, report that PEP is...

Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of Competence.

Psychedelic Medicine September 4, 2024 Shannon Dames, Crosbie Watler, Pamela Kryskow et al. 4 citations

Introduction: This perspective on experiential training delves into the potential benefits and counterarguments related to integrating firsthand experience of psychedelic-assisted therapy (PaT) to enhance the competency of trainees. The Case for Experiential Training as a Core PaT Competency: Experiential training serves a dual purpose: promoting therapists' mental wellness and refining their...

A Cross-Sectional Survey Investigating Māori and Non-Māori Cancer Patients' Views on Psychedelic-Assisted Therapy in Aotearoa New Zealand.

Journal of Psychoactive Drugs September 4, 2024 Georgia Best, Eva Morunga, Alesha Wells et al. 1 citation

People with cancer experience higher rates of psychological dysfunction than the general population, with extreme inequity among indigenous people. Psychedelic-assisted therapy (PAT) is a reemerging area with promising evidence as a treatment for mental health difficulties. The current study aimed to investigate the perceptions of PAT in indigenous (Māori) and non-indigenous cancer patients in...

DOI: 10.1080/02791072.2024.2397427 (opens in new tab) Psychedelic therapy Psychedelic-assisted treatment Hallucinogenic therapy Entheogenic medicine +22

The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials.

Psychiatry Research September 1, 2024 Jianhua Yang, Ni Wang, Wulin Luo et al. 14 citations

3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is one of the most widely used illicit substances worldwide. MDMA-assisted psychotherapy has become a novel treatment for posttraumatic stress disorder (PTSD), and many randomized controlled trials (RCTs) have been performed over the past decade. Therefore, this study aimed to systematically review and demonstrate the efficacy...

Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.

Psychedelic Medicine September 1, 2024 Michelle St Pierre, Lucas Standing, Yarissa Herman et al. 3 citations

A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...

DOI: 10.1089/psymed.2023.0060 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Barriers to access Physician communication Plant medicine +5

LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.

The British Journal of Psychiatry September 1, 2024 Friederike Holze, Peter Gasser, Felix Müller et al. 32 citations

Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with anxiety with or without life-threatening illness. This study was an a priori-planned long-term follow-up of an investigator-initiated, two-centre trial that used a double-blind,...

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].

Der Nervenarzt September 1, 2024 Johannes Jungwirth, Francesco Bavato, Boris B. Quednow 6 citations

With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of new psychotropic drugs, the psychiatric research into the clinical application of hallucinogens in psychiatry has literally blossomed in the last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic...

DOI: 10.1007/s00115-024-01727-0 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Clinical safety Addictive potential +5

Refractory CRPS pain treated with psilocybin: A case report

Clinical Case Reports September 1, 2024 David S Jevotovsky, Harman Chopra, Court Wing et al. 9 citations

Key Clinical Message Psilocybin shows promise as a treatment for CRPS, offering significant pain relief and functional improvement in a patient with refractory symptoms. This case highlights the need for further research into psilocybin's efficacy and optimal dosing for chronic pain management.

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.

Psychedelic Medicine September 1, 2024 Crystal Lederhos Smith, Nathan Sackett, Brian Connor Stark et al. 4 citations

There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, research has rapidly expanded in the past decade. Multiple states and cities have drafted their own policies regarding the use of psychedelics. Assuming interest in psychedelics continues to...

Psychedelic-Assisted Therapy in Clinical Practice

August 30, 2024

Psychedelic-assisted therapy involves preparation sessions, a supportive psychedelic session, and integration sessions to reinforce therapeutic insights. Psychological safety is a primary concern with psychedelics, and challenging experiences are managed through non-directive support rather than pharmacological intervention. Psychedelic-assisted therapy's unique paradigm poses challenges,...

Psychedelic‐assisted therapy for palliative care within a home treatment setting: A case report

Clinical Case Reports August 30, 2024 Seragnoli Federico, Martignoni Geo, Martignoni Entela et al. 3 citations

Key Clinical Message This case study describes the feasibility and safety of psychedelic‐assisted therapy (PAT) as a home‐based intervention for a patient with throat cancer experiencing significant existential distress. The patient tolerated the intervention well. This case supports the feasibility and safety of PAT for patients with life‐threatening conditions in a home setting. Abstract...

DOI: 10.1002/ccr3.9305 (opens in new tab) Psychedelic therapy Home treatment Palliative care Psychedelic‐assisted therapy +4

Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing

Journal of Management Inquiry August 28, 2024 Charlie Smith 1 citation

There is a psychedelic renaissance with key drugs that alter perception and mood being given breakthrough therapy status as potential treatments for common mental health conditions. If approved, these drugs may be used alongside psychedelic-assisted therapy (PAT), a therapeutic process supporting learning from taking psychedelics. Nearly 100 companies, mainly across America, Canada, Europe, and...

DOI: 10.1177/10564926241267208 (opens in new tab) Psychedelic therapy:psychedelic-assisted therapy Breakthrough therapy Corporate wellness Employee health +8

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review

Annals of Palliative Medicine August 22, 2024 Arum Kim, Barley Halton, Akash Shah et al. 11 citations

Existential distress is commonly experienced by patients diagnosed with a life-threatening illness. This condition has been shown to adversely impact quality of life and is correlated with increased suicidal ideation and requests for hastened death. While palliative care teams are experienced in treating depression and anxiety, existential distress is a distinct clinical condition for which...

DOI: 10.21037/apm-24-35 (opens in new tab) Psilocybin Psychotherapist Existentialism Distress